Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Add as a preferred source on Google
ATLANTA, Feb. 27, 2018 -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will present at the 38th Annual Cowen & Co. Health Care Conference to be held March 12-14, 2018 at the Boston Marriott Copley Place, Boston, Massachusetts. Alimera’s presentation will take place Tuesday, March 13 at 12:00PM.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of Alimera's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
[email protected]
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
[email protected]
